1-Phenoxycarbonylpiperidine-4-carboxylic acid | 1019352-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Phenoxycarbonylpiperidine-4-carboxylic acid
• CAS: 1019352-17-0
• 化学式: C₁₃H₁₅NO₄
• mdl: MFCD11522941
• 分子量: 249.266
• InChiKey: QPKLTTLAEUQYPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Phenoxycarbonylpiperidine-4-carboxylic acid 在 N-甲基吗啉 、 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 碘苯二乙酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 52.0h， 生成 (S)-4-oxo-3-(1-(phenoxycarbonyl)piperidine-4-carboxamido)-5-(2,3,5,6-tetra fluorophenoxy)pentanoic acid
  参考文献：
  名称：

  EP3456711

  摘要：

  公开号：
• 作为产物：
  描述：

  ethyl 1-phenoxycarbonyl-4-piperidinecarboxylic acid 在 锂硼氢 、 盐酸 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 2.25h， 生成 1-Phenoxycarbonylpiperidine-4-carboxylic acid
  参考文献：
  名称：

  WO2007/47496

  摘要：

  公开号：
• 作为试剂：
  描述：

  Fmoc-甘氨酸 、 N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 、 Fmoc-N-三苯甲基-L-天冬酰胺 、 N-芴甲氧羰基-L-谷氨酸 5-烯丙基酯 、 Fmoc-Pbf-L-精氨酸 在 1-Phenoxycarbonylpiperidine-4-carboxylic acid 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 哌啶 、 N,N-二甲基甲酰胺 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 0.58h， 以33%的产率得到c[KNGRE]-NH₂
  参考文献：
  名称：

  Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome

  摘要：

  The Asn-Gly-Arg (NGR) motif in both cyclic and linear form has previously been shown to specifically bind to CD13/aminopeptidase N that is selectively overexpressed in tumor vasculature and some tumor cells. However, previous versions of cyclic NGR used a liable disulfide bridge between cysteine residues that may be problematic for liposome targeting due to disulfide bond formation between adjacent peptides on the liposomal surface. In this study, we report the design, synthesis, and characterization of a novel cyclic NGR-containing peptide, cKNGRE, which does not contain a disulfide bridge. cKNGRE was synthesized in good yield and purity and attached to the fluorescent reporter Oregon Green (cKNGRE-OG) and lysolipid-containing temperature sensitive liposomes (LTSLs). The identity of cKNGRE was verified with NMR and mass spectral techniques. In vitro fluorescence microscopy evaluation of cKNGRE-OG demonstrated binding and active uptake by CD13(+) cancer cells and minimal binding to CD13(-) cancer cells. The cKNGRE-OG ligand displayed 3.6-fold greater affinity for CD13(+) cancer cells than a linear NGR-containing peptide. Affinity for CD13(+) cancer cells was similarly improved 10-fold for both the cyclic and linear NGR when presented in a multivalent fashion on the surface of an LTSL cKNGRE-targeted LTSLs rapidly released (>75% in <4 s) doxorubicin at 41.3 degrees C with minimal release at 37 degrees C. These results demonstrate the ability to synthesize a cKNGRE-targeted temperature sensitive liposome that lacks a disulfide bridge and has sufficient binding affinity for biological applications. Published by Elsevier B.V.

  DOI：

  10.1016/j.jconrel.2009.12.031

文献信息

• Structure-activity relationship study of a series of caspase inhibitors containing γ-amino acid moiety for treatment of cholestatic liver disease
  作者：Jianfeng Mou、Songliang Wu、Zhi Luo、Fengying Guo、Haiying He、Jianhua Wang、Fusen Lin、Fengxun Guo、Jianping Sun、Liang Shen、Minggao Zeng、Chuan Wang、Deming Xu、Zhengxian Gu、Xin Tian、Aiming Zhang、Hongjiang Xu、Ling Yang、Xiquan Zhang、Jian Li、Shuhui Chen

  DOI：10.1016/j.bmcl.2018.04.002

  日期：2018.6

  A series of caspase inhibitors containing γ-amino acid moiety have been synthesized. A systemic study on their structure-activity relationship of anti-apoptotic cellular activity is presented. These efforts led to the discovery of compound 20o as a potent caspase inhibitor, which demonstrated preclinical ameliorating total bilirubin efficacy with a significantly improved pharmacokinetic profile.

  已经合成了一系列含有γ-氨基酸部分的胱天蛋白酶抑制剂。对其抗凋亡细胞活性的构效关系进行了系统的研究。这些努力导致了化合物20o作为有效的半胱天冬酶抑制剂的发现，证明了临床前改善总胆红素功效并显着改善了药代动力学。
• 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them.
  申请人：Krogsgaard-Larsen, Povl

  公开号：EP0000167A1

  公开（公告）日：1979-01-10

  1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them. Compounds of formuta is which R" is hydrogen, acetyl or a group wherein R1 is C1-8 alkyl; phenyl; substituted phenyl, phenylalkyl in which the phenyl group may be substituted. R' is hydrogen; C1-8 alkyl; phenyl; substituted phenyl, phenylalkyl, substituted phenylalkyl or idanyl; or R' is a group wherein R2 and R3 are hydrogen; C1-6 alkyl; or phenylalkyl and R4 designates C1-8 alkyl; phenyl; substituted phenyl or phenylalkyl and salts thereof. Intermediates for preparing (1) are in which Z is hydrogen or a protecting group and W is hydrogen or a readily removable group and saits thereof which are subjected to dehydration and in which Z' and W' have the same meaning as and W and salts thereof, which are reacted with appropriate reagents. The compounds (I) exhibit γ-aminobutyric acid related activity and are useful as active ingredients in pharmaceutical compositions. They may additionally contain a minor tranquilizer or a neuroleptic.

  1,2,3,6-四氢异烟酸及其衍生物、制备它们的方法和起始产品，以及含有它们的药物组合物。化合物 其中 R "是氢、乙酰基或一个基团 其中 R1 是 C1-8 烷基；苯基；取代苯基；苯基烷基，其中苯基可被取代。R'是氢；C1-8 烷基；苯基；取代的苯基、苯基烷基、取代的苯基烷基或偶氮苯基；或 R'是一个基团，其中 R2 和 R3 是氢；C1-6 烷基；或苯基烷基，R4 表示 C1-8 烷基；苯基；取代的苯基或苯基烷基及其盐。制备（1）的中间体有 其中 Z 为氢或保护基，W 为氢或易脱去的基团及其经脱水处理的盐，以及 其中 Z'和 W'的含义与 W 及其盐类相同，它们与适当的试剂反应。 化合物（I）具有与γ-氨基丁酸相关的活性，可用作药物组合物中的活性成分。此外，它们还可能含有轻微的镇静剂或神经安定剂。
• CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3456711A1

  公开（公告）日：2019-03-20

  Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

  公开了一类作为 Caspase 抑制剂的化合物，特别是如式（I）所示的化合物或其药学上可接受的盐，以及该化合物在治疗 Caspase 相关疾病中的用途。
• Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US10981860B2

  公开（公告）日：2021-04-20

  Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

  公开了一类作为 Caspase 抑制剂的化合物，特别是如式（I）所示的化合物或其药学上可接受的盐，以及该化合物在治疗 Caspase 相关疾病中的用途。
• WO2007/44001
  申请人：——

  公开号：——

  公开（公告）日：——